YESCARTA Drug Insight and Market Forecast - 2032

"YESCARTA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about YESCARTA for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the YESCARTA for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the YESCARTA for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the YESCARTA market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

YESCARTA (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy. YESCARTA, a patient's T cells are harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising a murine anti-CD19 single-chain variable fragment (scFv) linked to CD28 and CD3-zeta costimulatory domains. The anti-CD19 CAR-T cells are expanded and infused back into the patient, where they can recognize and eliminate CD19-expressing target cells.

YESCARTA binds to CD19-expressing cancer cells and normal B cells. Studies demonstrated that following anti-CD19 CAR-T-cell engagement with CD19-expressing target cells, the CD28 and CD3-zeta costimulatory domains activate downstream signaling cascades that lead to T-cell activation, proliferation, acquisition of effector functions and secretion of inflammatory cytokines and chemokines. This sequence of events leads to the killing of CD19-expressing cells. The therapy is indicated to treat adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy (third line of therapy) (National Cancer Institute, 2022). The company is planning to file the application for YESCARTA in 1L setting on the basis of ZUMA-23 in 2025 or beyond.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the YESCARTA description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on YESCARTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the YESCARTA research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around YESCARTA.
• The report contains forecasted sales of YESCARTA for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for YESCARTA in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

YESCARTA Analytical Perspective by DelveInsight

In-depth YESCARTA Market Assessment

This report provides a detailed market assessment of YESCARTA for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

YESCARTA Clinical Assessment

The report provides the clinical trials information of YESCARTA for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence YESCARTA dominance.
• Other emerging products for DLBCL are expected to give tough market competition to YESCARTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of YESCARTA in DLBCL.
• Our in-depth analysis of the forecasted sales data of YESCARTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the YESCARTA in DLBCL.

Key Questions:

• What is the product type, route of administration and mechanism of action of YESCARTA?
• What is the clinical trial status of the study related to YESCARTA in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the YESCARTA development?
• What are the key designations that have been granted to YESCARTA for DLBCL?
• What is the forecasted market scenario of YESCARTA for DLBCL?
• What are the forecasted sales of YESCARTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to YESCARTA for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?